Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Net Income towards Common Stockholders (2020 - 2025)

Historic Net Income towards Common Stockholders for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to -$74.0 million.

  • Relay Therapeutics' Net Income towards Common Stockholders rose 1601.79% to -$74.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$296.8 million, marking a year-over-year increase of 1402.79%. This contributed to the annual value of -$337.7 million for FY2024, which is 123.79% up from last year.
  • Relay Therapeutics' Net Income towards Common Stockholders amounted to -$74.0 million in Q3 2025, which was up 1601.79% from -$69.7 million recorded in Q2 2025.
  • In the past 5 years, Relay Therapeutics' Net Income towards Common Stockholders registered a high of -$42.2 million during Q1 2021, and its lowest value of -$193.4 million during Q2 2021.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$76.8 million (2022), whereas its average is -$81.8 million.
  • Examining YoY changes over the last 5 years, Relay Therapeutics' Net Income towards Common Stockholders showed a top increase of 7155.57% in 2021 and a maximum decrease of 62369.41% in 2021.
  • Quarter analysis of 5 years shows Relay Therapeutics' Net Income towards Common Stockholders stood at -$67.5 million in 2021, then dropped by 0.03% to -$67.5 million in 2022, then dropped by 23.74% to -$83.5 million in 2023, then grew by 8.97% to -$76.0 million in 2024, then increased by 2.66% to -$74.0 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$74.0 million for Q3 2025, versus -$69.7 million for Q2 2025 and -$77.1 million for Q1 2025.